Scientists at Weill Cornell Medicine say they’ve identified how ketamine produces its rapid antidepressant effects — a breakthrough that could lead to new treatments with fewer risks.
In a pair of new studies, researchers mapped the biological pathways behind ketamine’s impact on the brain, offering a clearer picture of how the drug works and how its benefits might be replicated without its well-known side effects.
Ketamine has emerged as a fast-acting option for patients with treatment-resistant depression, but its effects are often short-lived and can come with serious complications, including changes in blood pressure, dissociation, and potential for addiction.
Researchers found that ketamine targets a specific group of opioid receptors in the brain’s prefrontal cortex, a region tied to mood and behavior. By activating those receptors, the drug temporarily reduces overactivity in certain brain cells, allowing other neural pathways to “reawaken” and restore function.
That initial effect may last only minutes, but scientists say it appears to trigger a cascade of changes that improve mood.
Building on that discovery, the research team was able to recreate similar antidepressant effects in preclinical models by combining low doses of three different drugs that act on the same pathway — a strategy that could reduce side effects by avoiding higher doses of any single medication.
A second study explored how ketamine’s longer-term benefits are maintained. Researchers identified key interactions between receptors in brain cells that strengthen communication between neurons and help sustain antidepressant effects over time.
The findings could reshape how depression is treated, shifting away from trial-and-error prescribing toward more targeted therapies based on how drugs interact with specific brain systems.
Researchers say clinical trials are now being planned to test whether combinations of existing medications can safely reproduce ketamine’s benefits in patients.
The work represents a step toward faster-acting, more precise treatments for depression — particularly for patients who don’t respond to traditional medications.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].